Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.

Miele, L., Napodano, C., Cesario, A., De Magistris, A., Pocino, K., Basile, U., Rapaccini, G. L., Gasbarrini, A., Grieco, A., COVID-19, adaptative immune response and metabolic-associated liver disease, <<LIVER INTERNATIONAL>>, N/A; 41 (11): 2560-2577. [doi:10.1111/liv.15061] [http://hdl.handle.net/10807/206298]

COVID-19, adaptative immune response and metabolic-associated liver disease

Miele, Luca
;
Napodano, Cecilia;Cesario, Alfredo;Pocino, Krizia;Basile, Umberto;Rapaccini, Gian Ludovico;Gasbarrini, Antonio;Grieco, A.
2021

Abstract

Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.
2021
Inglese
Miele, L., Napodano, C., Cesario, A., De Magistris, A., Pocino, K., Basile, U., Rapaccini, G. L., Gasbarrini, A., Grieco, A., COVID-19, adaptative immune response and metabolic-associated liver disease, <<LIVER INTERNATIONAL>>, N/A; 41 (11): 2560-2577. [doi:10.1111/liv.15061] [http://hdl.handle.net/10807/206298]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/206298
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 2
social impact